Earnings shock puts FMC under closer investor scrutiny

FMC (FMC) has come under renewed focus after reporting a second quarter net loss of US$186.6 million on sales of US$867.1 million, compared with net income of US$66.7 million a year earlier.

The company also issued updated 2026 revenue guidance and outlined plans to pay down about US$1b of debt in 2026 through asset sales and licensing agreements, giving investors new data points to reassess FMC stock.

Against this backdrop, FMC's share price has fallen 19.2% over the past 90 days and is down 26.2% year to date, while the 1 year total shareholder return has declined 69.4%. This points to fading momentum as investors reassess risk after recent losses and guidance.

If FMC's recent volatility has you thinking about diversification, this could be a good moment to look at other opportunities linked to real assets such as 9 top copper producer stocks

After such a steep reset in FMC's share price and guidance, it is worth asking how much of the bad news is already in the stock and how much potential upside, if any, still lies ahead as the valuation resets.

Most Popular Narrative: 33.2% Undervalued

FMC's most followed narrative estimates fair value at $15.84 a share versus the recent $10.59 close, which suggests the market and narrative are telling very different stories right now.

Ongoing cost transformation, including lower manufacturing costs for key products like Rynaxypyr and benefits from 2024-2025 restructuring, creates durable COGS reductions and improved fixed cost absorption. This serves as a catalyst for sustainable EBITDA and net margin improvement. The shift away from direct commercial operations in India to a lower-risk, B2B supply model frees up cash for debt reduction, enhances the balance sheet, and enables redeployment of capital toward high-value innovation and growth portfolios, which is expected to have a positive impact on net earnings over the long term.

Want to see what sits underneath that fair value for FMC? The narrative leans heavily on a sharp earnings repair, steadier margins and a future earnings multiple that is lower than many peers. The exact mix of revenue growth, profitability and discount rate assumptions might surprise you.

Result: Fair Value of $15.84 (UNDERVALUED)

However, FMC's story can still break if regulatory setbacks on key crop protection products or slower than expected debt reduction force analysts to reconsider that valuation path.

Next Steps

Given the mix of pressure and potential around FMC, it makes sense to move quickly and look at the data first hand so you can weigh the trade off between concern and optimism on your own terms with 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond FMC?

If FMC has sharpened your focus on risk and reward, now is the time to broaden your watchlist and spot other opportunities before they move without you.

• Scan for potential mispriced opportunities that pair strong fundamentals with attractive valuations through the 52 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with higher yields and consistent payouts in the 8 dividend fortresses.
• Reduce downside shocks by focusing on companies that score well on resilience and financial risk in the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.